Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.

The GameChanger
Insulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.

Jen Moulton, RPh
President + Founder
CEimpact

Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Wang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.

https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the chemical and structural changes that make icodec different from other basal insulins
2. Discuss the results of the meta-analysis about insulin icodec

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-043-H01-P
Initial release date: 1/29/2024
Expiration date: 1/29/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram